Young survivors of acute myeloid leukemia have long-term complications from treatment

November 09, 2020

Adolescent and young adult (AYA) patients treated for acute myeloid leukemia (AML) have a high risk of developing several long-term health complications, a study led by UC Davis Comprehensive Cancer Center researchers has found.

The most common complications among AYA survivors (ages 15–39) were cardiovascular, endocrine and respiratory diseases. The complications - known as late effects - were more present among non-white AYA patients and those living in more deprived neighborhoods.

“Our study shed light on the high burden of late effects among young survivors of AML,” said Renata Abrahão, the study’s lead author. Abrahão is a postdoctoral fellow at the UC Davis Comprehensive Cancer Center and the Center for Healthcare Policy and Research.

According to the American Cancer Society, around 20,000 cases of AML will be diagnosed in 2020 in the U.S. alone. With AML, the myeloid cells produced inside the bone marrow grow abnormally. The main treatment for most types of AML is chemotherapy. In some cases, it might be followed by a stem cell transplant.

Late effects of AML linked to health disparities

The study used comprehensive information from 1168 AYA patients with AML. These patient cases were reported to the California Cancer Registry from all non-federal hospitals in California between 1996 and 2012.

The researchers found that after 10 years of AML diagnosis, some patients developed an endocrine disease (26%), a cardiovascular disease (19%) and a respiratory disease (7%). Other late effects were less frequent but included serious illnesses such as another cancer. The study found that AYA survivors who underwent bone marrow transplant were at least twice as likely to experience most of the late effects.

Hispanic, Black and Asian/Pacific Islander survivors were at a higher risk of many of the late effect diseases. The study showed that AYA survivors who lived in poorer neighborhoods at the time of AML diagnosis had more of these late effects.

According to the researchers, many factors can lead to the disparities in disease burden. These include differences in therapeutic management, patient’s response to treatment, AML with high-risk mutations, coexisting diseases and socioeconomic factors.

“This higher risk may relate to the financial hardship that patients with cancer often experience. As a result of cancer, AYA survivors and their families may miss work, experience income loss and incur substantial out-of-pocket expenses,” said Theresa Keegan. Keegan is an associate professor at the UC Davis Comprehensive Cancer Center and the study’s senior author.

AYA patients suffer a higher financial burden compared to younger or older cancer survivors. They may forgo treatment and long-term follow-up visits that could mitigate the impact of late effects. Their risk of late effects may be compounded by unhealthy lifestyle habits such as smoking, excessive alcohol consumption, lack of exercise, non-protected sun exposure and poor diet.

“Our findings can help clinicians and policymakers develop better survivorship care plans to reduce suffering and death among AYA survivors of AML,” Abrahão said.

The study was published Nov. 9 in the International Journal of Epidemiology.

This study was supported by the Rich and Weissman Family Lymphoma and Survivorship Fund, St. Baldrick’s Research Grant, the National Research Service Award (NRSA) for Primary Medical Care, from the Health Resources and Services Administration (HRSA) [T32HP300370401].

The co-authors on this work are Jasmine C. Huynh and Qian W. Li from the UC Davis Comprehensive Cancer Center; David J. Benjamin of University of California, Irvine; Lena E. Winestone of University of California, San Francisco; and Lori Muffly of Stanford University.

Article: Abrahão et al. (2020) Chronic medical conditions and late effects after acute myeloid leukemia in adolescents and young adults: a population-based study. International Journal of Epidemiology. Doi: 10.1093/ije/dyaa184

University of California - Davis Health

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to